Atossa Therapeutics, Inc. continues to navigate a volatile period within the biotechnology sector, maintaining its strategic focus on the discovery of proprietary therapeutics and advanced delivery methods specifically targeting breast cancer and related oncological conditions. Headquartered in Seattle, Washington, the company operates on a global scale, positioning itself within the highly competitive health care equipment and supplies industry.
The company’s market position reflects the high-risk, high-reward nature of the oncology drug development landscape. As of the market close on November 12, 2026, Atossa Therapeutics was trading at $1.96 on the Nasdaq. This valuation follows a period of significant price fluctuation; the stock reached a 52-week high of $14.85 in December 2025, but has since faced downward pressure, hitting a 52-week low of $1.70 in June 2026.
With a current market capitalization of approximately $19.56 million, Atossa remains a specialized player in the biopharmaceutical space. The company’s current price-to-earnings (P/E) ratio stands at -0.51, a metric consistent with biotechnology firms heavily invested in research and development phases where immediate profitability is secondary to the long-term potential of their therapeutic pipeline.
As Atossa Therapeutics continues to pursue innovative solutions for unmet patient needs in oncology, the company’s ability to advance its proprietary delivery technologies will be the critical determinant of its future valuation. For investors and industry observers, the focus remains on whether the company’s specialized research can translate into clinical milestones that justify its previous market highs.




